Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-09-23 8:56 pm Purchase | 2024-09-16 | 13D | Zenas BioPharma, Inc. ZBIO | SR ONE CAPITAL MANAGEMENT LLC | 4,911,539 12.300% | 4,911,539 (New Position) | Filing History |
| 2024-07-08 8:54 pm Purchase | 2024-06-28 | 13D | Kala Pharmaceuticals, Inc. KALA | SR ONE CAPITAL MANAGEMENT LLC | 445,643 9.990% | 445,643 (New Position) | Filing History |
| 2024-03-25 6:41 pm Sale | 2024-03-21 | 13D | Arcellx, Inc. ACLX | SR ONE CAPITAL MANAGEMENT LLC | 2,346,630 4.440% | -800,000 (-25.42%) | Filing History |
| 2024-02-09 8:14 pm Sale | 2023-12-31 | 13G | eFFECTOR Therapeutics, Inc. EFTR | SR ONE CAPITAL MANAGEMENT LLC | 0 0.000% | -272,885 (Position Closed) | Filing History |
| 2023-12-18 4:16 pm Sale | 2023-12-14 | 13D | Arcellx, Inc. ACLX | SR ONE CAPITAL MANAGEMENT LLC | 3,146,630 6.460% | -800,000 (-20.27%) | Filing History |
| 2023-06-02 4:46 pm Sale | 2023-05-31 | 13D | Arcellx, Inc. ACLX | SR ONE CAPITAL MANAGEMENT LLC | 3,946,630 8.220% | -540,544 (-12.05%) | Filing History |
| 2023-05-19 5:02 pm Sale | 2023-05-11 | 13D | Arcellx, Inc. ACLX | SR ONE CAPITAL MANAGEMENT LLC | 4,487,174 9.350% | -1,012,833 (-18.42%) | Filing History |
| 2022-06-27 4:35 pm Unchanged | 2022-06-21 | 13D | Arcellx, Inc. ACLX | SR ONE CAPITAL MANAGEMENT LLC | 5,500,007 12.900% | 0 (Unchanged) | Filing History |
| 2022-02-17 12:46 pm Purchase | 2022-02-08 | 13D | Arcellx, Inc. ACLX | SR ONE CAPITAL MANAGEMENT LLC | 5,500,007 15.800% | 5,500,007 (New Position) | Filing History |
| 2022-02-11 8:35 pm Purchase | 2021-12-31 | 13G | eFFECTOR Therapeutics, Inc. EFTR | SR ONE CAPITAL MANAGEMENT LLC | 272,885 16.900% | 272,885 (New Position) | Filing History |